Eli Lilly and Company (ETR:LLY)

Market Cap	781.64B +19.6%
Revenue (ttm)	50.64B +45.4%
Net Income	15.69B +120.0%
EPS	17.42 +121.0%
Shares Out	n/a
PE Ratio	49.81
Forward PE	32.65
Dividend	5.35 (0.61%)
Ex-Dividend Date	Nov 14, 2025

Volume	783
Average Volume	1,599
Open	873.50
Previous Close	873.50
Day's Range	871.70 - 882.50
52-Week Range	535.80 - 971.10
Beta	0.35
RSI	46.70
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD